Kethandapatti Balaji
Urology · Jacksonville, FLNPI 1558314484
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Bayer at 43.6% of the total. Reporting peaked in 2022 at $9,167 and has fallen 92.5% since, to $689 in 2025. Among urology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $301.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$13K
- Telix Pharmaceuticals$4K
- Janssen Scientific Affairs, LLC$3K
- Intuitive Surgical$2K
- AstraZeneca$2K
- Exelixis Inc.$2K
- plus $4K from 16 others
Across 60 payments — averaging $6409.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Macrogenics, Inc.$123K
- Janssen Research & Development, LLC$64K
- Exelixis Inc.$44K
- Davol Inc.$41K
- AstraZeneca$33K
- Telix Pharmaceuticals$32K
- plus $48K from 4 others
What the payments were for
- Consulting fees$15,65052%
- Travel & lodging$8,66129%
- Food & beverage$4,81116%
- Education$7503%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 20 | $13,026 |
| Telix Pharmaceuticals | 14 | $3,840 |
| Janssen Scientific Affairs, LLC | 9 | $3,464 |
| Intuitive Surgical | 12 | $2,071 |
| AstraZeneca | 2 | $1,933 |
| Exelixis Inc. | 9 | $1,671 |
| Johnson & Johnson | 1 | $1,090 |
| Cook Medical LLC | 4 | $475 |
| Teleflex LLC | 4 | $285 |
| Coloplast | 2 | $284 |
| Astellas Pharma US Inc | 4 | $270 |
| Boston Scientific | 2 | $234 |
| Bioprotect Medical, Inc. | 1 | $160 |
| Olympus America Inc. | 2 | $134 |
| Profound Medical Corp. | 1 | $134 |
| Axonics, Inc. | 1 | $126 |
| Amgen | 1 | $124 |
| Ambu Inc. | 1 | $123 |
| Urogen Pharma, Inc. | 1 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $111 |
| Ferring Pharmaceuticals Inc. | 1 | $110 |
| Blue Earth Diagnostics | 2 | $88 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nubeqa$8,323
- Xofigo$5,958
- Non-Covered$4,450
- ILLUCCIX$3,887
- LYNPARZA$1,880
- Da Vinci Surgical System$1,150
- DA VINCI SP$750
- TITAN$284
- BIOPROTECT BALLOON IMPLANT SYSTEM$160
- RESONANCE$136
- Barrigel$134
- Tulsa-Pro$134
- rezum Generator$130
- Cook Medical Stents$130
- Axonics$126
- IMDELLTRA (AMG 757)$124
- JELMYTO$120
- UroLift$113
- ADSTILADRIN$110
- LITHO 150$108
How this compares
$29,871 in reported general payments places this provider in the 90th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 11 | $156,014 |
| NubeqaDarolutamide | 11 | $142,003 |
| Abiraterone Acetate | 81 | $125,561 |
| Prednisone | 14 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $270 | $156,01411 claims |
| BayerNubeqa | $13,026 | $142,00311 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $3,464 | $125,56181 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 urology providers in Florida.
Other urology in Jacksonville
- Raymond PakJacksonville$251K
- Douglas SwartzJacksonville$118K
- Ali KasraeianJacksonville$63K
- Sagar ShahJacksonville$60K
- Bryce BairdJacksonville$56K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.